149299-82-1

Basic information

• Product Name: Hydroxy-PEG2-CH2CO2t-Bu
• Synonyms: Hydroxy-PEG2-CH2CO2t-Bu;Hydroxy-PEG2-CH2COOtBu;HO-PEG2-CH2COOtBu;tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate;OH-PEG2-CH2COOtBu
• CAS NO: 149299-82-1
• Molecular Formula: C₁₀H₂₀O₅
• Molecular Weight: 220.2628
• Mol File: 149299-82-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 306.1±22.0 °C(Predicted)
• Appearance: /
• Density: 1.062±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Soluble in Water, DMSO, DCM, DMF
• PKA: 14.35±0.10(Predicted)
• CAS DataBase Reference: Hydroxy-PEG2-CH2CO2t-Bu(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxy-PEG2-CH2CO2t-Bu(149299-82-1)
• EPA Substance Registry System: Hydroxy-PEG2-CH2CO2t-Bu(149299-82-1)

Safety Data

• Hazardous Substances Data: 149299-82-1(Hazardous Substances Data)

Usage

Description

Hydroxy-PEG2-CH2CO2t-Bu is a PEG (polyethylene glycol) linker that features a hydroxyl group and a t-butyl protected carboxyl group. This molecule is characterized by its hydrophilic PEG spacer, which enhances solubility in aqueous environments. The presence of the hydroxyl group allows for further chemical modifications or the attachment of other reactive functional groups. Additionally, the t-butyl protected carboxyl group can be removed under acidic conditions, providing versatility in its applications.

Uses

Used in Pharmaceutical Research:
Hydroxy-PEG2-CH2CO2t-Bu is used as a reagent for the preparation of potentiator-corrector agonists targeting the ΔF508-CFTR mutant protein associated with cystic fibrosis. Its unique structure and functional groups make it a valuable tool in the development of therapeutic agents for this genetic disorder.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Hydroxy-PEG2-CH2CO2t-Bu can be utilized as a component in the design of drug delivery systems. Its hydrophilic nature and the ability to modify the hydroxyl and carboxyl groups make it suitable for creating targeted drug carriers or improving the solubility and bioavailability of certain drugs.
Used in Chemical Synthesis:
Hydroxy-PEG2-CH2CO2t-Bu can also be employed in chemical synthesis as a versatile building block. The t-butyl protected carboxyl group allows for selective deprotection, enabling the synthesis of a variety of PEGylated compounds with potential applications in various fields, including medicine, materials science, and biotechnology.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 10049-21-5 sodium dihydrogenphosphate 
• 111-46-6 diethylene glycol 

Downstream Products

• 882518-89-0 tert-butyl 2-[2-[2-(p-tolylsulfonyloxy)ethoxy]ethoxy]acetate 
• 1144518-54-6 {2-[2-(4-chloro-2-nitrophenoxy)ethoxy]ethoxy}acetic acid tert-butyl ester 

Relevant articles and documents

Protein degradation through covalent inhibitor-based PROTACs

Tremendous advancements in proteolysis targeting chimera (PROTAC) technology have been made in recent years. However, whether a covalent inhibitor-based PROTAC can be developed remains controversial. Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.

Compound targeting ubiquitination degradation tyrosinase as well as preparation method and application thereof

A Tyr inhibitor kojic acid is covalently bound to a pomalidomide or VHL enzyme targeting ligand through a linkage chain to obtain a specific structure, and the preparation method is simple to operate and mild in condition. The generation of melanin is inhibited, the anti-melanin tumor effect is remarkable, and the safety period of vegetables and fruits can be remarkably prolonged. The compound targeted ubiquitination degradation tyrosinase provided by the invention has wide application prospects in medicine, food and cosmetics.

PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES

The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/ inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Such diseases or disorders are alpha-synucleinopathies or neurodegenerative diseases associated with alpha-synuclein accumulation and aggregation, such as e.g. Parkinson Disease, Alzheimer's Disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson's Disease.